Connor, Clark & Lunn Investment Management (CC&L)’s Eton Pharmaceutcials ETON Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ETON Stock Details ETON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Sell	42,693 -33,893	-44%	-$593K	﹤0.01%	1146
2025 Q4	$1.3M	Sell	76,586 -67,225	-47%	-$1.18M	﹤0.01%	1048
2025 Q3	$3.13M	Sell	143,811 -78,272	-35%	-$1.3M	0.01%	713
2025 Q2	$3.16M	Sell	222,083 -10,449	-4%	-$165K	0.01%	715
2025 Q1	$3.02M	Buy	232,532 +17,654	+8%	+$267K	0.01%	622
2024 Q4	$2.86M	Buy	214,878 +149,864	+231%	+$1.52M	0.01%	631
2024 Q3	$390K	Buy	65,014 +30,167	+87%	+$128K	﹤0.01%	1158
2024 Q2	$115K	Sell	34,847 -4,450	-11%	-$15.6K	﹤0.01%	1304
2024 Q1	$147K	Sell	39,297 -3,781	-9%	-$16.5K	﹤0.01%	1430
2023 Q4	$189K	Buy	43,078 +4,773	+12%	+$19.1K	﹤0.01%	1268
2023 Q3	$160K	Buy	+38,305	New	+$148K	﹤0.01%	1256

Other funds holding ETON

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NPT

National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ETON Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Eton Pharmaceutcials (ETON) stake by 44% in Q1 2026, selling an estimated $593K and leaving 42,693 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ETON in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.16M in Q2 2025. 116 funds tracked by Wall St. Rank hold ETON as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 42,693 shares of Eton Pharmaceutcials worth $1.05M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 33,893 Eton Pharmaceutcials shares in Q1 2026, an estimated $593K.
Eton Pharmaceutcials made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1146 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Eton Pharmaceutcials in Q3 2023 and has held it in 11 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Eton Pharmaceutcials position peaked at $3.16M in Q2 2025.
116 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.